Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy for Patients With Cancer of the Stomach

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological proven adenocarcinoma of the esophagus or the ventricle (ECV), and which cannot be treated curatively.~2. Age ≥ 18 years.~3. WHO performance status 0-1.~4. Neutrophils ≥ 1,5 x 109/L and platelets ≥ 100 x 109/L.~5. Bilirubin ≤ 1,5 x UNL (Upper Normal Limit) and ASAT and/or ALAT ≤ 3 x UNL.~6. Creatinine-clearance ≥ 60 ml/min.~7. Planned first day of treatment within 8 days after inclusion in the study.~8. Signed consent form.~Exclusion Criteria:~1. No previous treatment with chemotherapy, except for (neo)-adjuvant chemotherapy for adenocarcinoma - treatment should have been completed at least 6 months before entrance in this study.~2. No sensory neuropathy.~3. No previously treatment with docetaxel, oxaliplatin or S1.~4. No clinical suspicion of brain metastases.~5. No cytotoxic treatment or other experimental treatment within 2 weeks of inclusion in the study.~6. Other serious disease (i.e. heart disease, AMI within 1 year or ongoing infection).~7. No pregnant women or women who are lactating. Patients who are not using contraception.~8. No known DPD-deficiency or known allergy to taxanes or platinum.~9. No signs of physical or mental illness that would prevent absorption of oral treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- DOS2W Dose level 1A (Type: EXPERIMENTAL): Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
- DOS2W Dose level 2A (Type: EXPERIMENTAL): Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
- DOS2W Dose level 3A (Type: EXPERIMENTAL): Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
- DOS2W Dose level 4A (Type: EXPERIMENTAL): Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
- DOS3W Dose level 1B (Type: EXPERIMENTAL): Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.
- DOS3W Dose level 2B (Type: EXPERIMENTAL): Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.
- DOS3W Dose level 3B (Type: EXPERIMENTAL): Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).